---
title: "R3 Vascular announces first patient treated in ELITE-BTK pivotal trial"
date: "2025-04-25T14:07:44.000Z"
publishedDate: "25 avril 2025"
summary: "R3 Vascular recently announced that the first patient in its ELITE-BTK pivotal trial has been treated by Brian DeRubertis (New York-Presbyterian and Weill Cornell Medicine, New York, USA). The trial evaluates R3 Vascular’s next-generation drug-eluting bioresorbable scaffold, Magnitude, for below-the-knee (BTK) peripheral arterial disease (PAD)."
importance: ""
sourceUrl: "https://vascularnews.com/r3-vascular-announces-first-patient-treated-in-elite-btk-pivotal-trial/"
tags: ["France", "Actualité", "Vascular News — Latest"]
permalink: "/papers/2025-04-25-r3-vascular-announces-first-patient-treated-in-elite-btk-pivotal-trial"
imageUrl: "https://vascularnews.com/wp-content/uploads/sites/7/2020/10/R3-Vascular-logo-web.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://vascularnews.com/r3-vascular-announces-first-patient-treated-in-elite-btk-pivotal-trial/"
---

![R3 Vascular announces first patient treated in ELITE-BTK pivotal trial](https://vascularnews.com/wp-content/uploads/sites/7/2020/10/R3-Vascular-logo-web.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://vascularnews.com/r3-vascular-announces-first-patient-treated-in-elite-btk-pivotal-trial/*

## L’essentiel

R3 Vascular recently announced that the first patient in its ELITE-BTK pivotal trial has been treated by Brian DeRubertis (New York-Presbyterian and Weill Cornell Medicine, New York, USA). The trial evaluates R3 Vascular’s next-generation drug-eluting bioresorbable scaffold, Magnitude, for below-the-knee (BTK) peripheral arterial disease (PAD).

## Lien source

https://vascularnews.com/r3-vascular-announces-first-patient-treated-in-elite-btk-pivotal-trial/
